Pharmsynthesis reported for 3 months of 2026 under RAS

Pharmsynthesis' RAS loss for 3 months of 2026 amounted to ₽36 million, which is two times lower than the ₽74 million loss in the previous year. Revenue decreased by 7.8% to ₽23.6 million, compared to ₽25.6 million a year earlier.